Oxyntomodulin: Actions and role in diabetes

  • Peptides. 2018 Feb:100:48-53. doi: 10.1016/j.peptides.2017.09.018.
Jens J Holst  1 Nicolai J Wewer Albrechtsen  2 Maria Buur Nordskov Gabe  2 Mette Marie Rosenkilde  2
Affiliations
  • 1. Department of Biomedical Sciences & Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. Electronic address: [email protected].
  • 2. Department of Biomedical Sciences & Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Abstract

Oxyntomodulin is a product of the glucagon precursor, proglucagon, produced and released from the endocrine L-cells of the gut after enzymatic processing by the precursor prohormone convertase 1/3. It corresponds to the proglucagon sequence 33-69 and thus contains the entire glucagon sequence plus a C-terminal octapeptide, comprising in total 37 Amino acids. As might have been expected, it has glucagon-like bioactivity, but also and more surprisingly also activates the receptor for GLP-1. This has given the molecule an interesting status as a glucagon-GLP-1 co-agonist, which is currently attracting considerable interest for its potential in the treatment of diabetes and obesity. Here, we provide an update on oxyntomodulin with a focus on its potential role in metabolic diseases.

Keywords
Diabetes; Oxyntomodulin; Proglucagon.
Products